Description
SinoMab BioScience Ltd is a biopharmaceutical company. The company is engaged in the research, development, manufacturing, and commercialization of therapeutics for the treatment of immunological diseases, primarily monoclonal antibody (mAb)-based biologics. Its flagship product, SM03 (Suciraslimab), is a potential global first-in target mAb for the treatment of rheumatoid arthritis (RA) and potentially for the treatment of other immunological diseases such as systemic lupus erythematosus (SLE), Sjogren’s syndrome (SS) as well as non-Hodgkin’s lymphoma (NHL), and other indications. The group derives revenue from Hong Kong.